(MOI)-dependent manner, with higher efficiency by AAV6 (Fig.  1b,c and Supplementary Fig. 1c ). With Illumina Nextera amplicon library prep, next-generation sequencing (NGS) analysis showed on-target mutagenesis at the DNA level as evident by insertions and deletions (indels), which is also MOI dependent ( Supplementary  Fig. 1d ). We constructed an AAV vector carrying a crRNA array targeting both TRAC and PDCD1 loci (crTRAC;crPDCD1), and showed that one transduction simultaneously generated editing in both loci using either AAV9 or AAV6, with the latter having high efficiency ( Supplementary Fig. 2a-d) . With AAV6-crTRAC;crPDCD1, NGS quantification showed that mutation efficiencies at TRAC and PDCD1 loci in bulk unsorted cells reached 60.39% and 80.07%, respectively (Fig. 1d ), which was further enriched by FACS on the TCRpopulation (78.80% and 83.63%, respectively) ( Fig. 1d ). These data demonstrated that AAV6 delivery of crRNA array with LbCpf1 mRNA electroporation is an efficient means for multiplexed editing in human primary T cells.
Modular and simultaneous knock-in and knockout in human primary T cells. We then leveraged the AAV vector to simultaneously deliver HDR template and crRNA array. We first tested knock-in of the reporter gene dTomato into TRAC with simultaneous PDCD1 knockout, using a single AAV construct, PDCD1 KO ;dTomato-TRAC KI (TRAC-KIKO) ( Fig. 2a and Supplementary Fig. 3a ). Five days after electroporation and transduction, TRAC-KIKO mediated efficient, targeted dTomato integration as measured by flow cytometry (Fig. 2a ). By staining CD3 that forms a surface complex with TCR 21 , we detected TRAC:CD3 knockdown efficiency at >70%, with on-target integration of dTomato at >40% of total CD4 + T cells ( Fig. 2a and Supplementary Fig. 4a ). We used a semiquantitative In-Out PCR and confirmed dTomato-TRAC integration at the DNA level, with bulk HDR efficiency at 34.7% in unsorted cells and enriched to 69.5% in CD3 -dTomato + -sorted cells by gel quantification ( Supplementary Fig. 3b ). NGS revealed the HDR junctions ( Supplementary Fig. 3c ), and also quantified the dTomato-TRAC HDR at 42.18% and 72.84% in bulk and enriched populations, respectively, with simultaneous measurements of TRAC wild-type (WT) and NHEJ alleles ( Supplementary Fig. 3d ). In the same samples, PDCD1 knockout as indels at the predicted cleavage sites were also observed at bulk frequencies of 47% and 72% by 5' 3' m7G AAAAAA Supplementary Fig. 1c . d, Top, schematic of a double-knockout AAV6-crRNA array targeting PDCD1 and TRAC. Bottom, quantification of the frequency of CRISPR-Cpf1-mediated double knockout of PDCD1 and TRAC from human primary CD4 + T cells after AAV6 infection for 5 d (n = 3 independent infection replicates). Unpaired two-sided t-test was used to assess significance. Knockout versus vector, ***P < 0.001 for all comparisons. Precise P values, up to the precision of 1 × 10 −15 , are provided in Supplementary Data 1, similarly thereafter. Data are shown as mean ± s.e.m., plus individual data points on the graph. ITR, inverted terminal repeat.
T7E1 (NGS 62.34% and 87.03%) in unsorted and TCR -dTomato +sorted cells ( Supplementary Fig. 3e ,f). The T7E1 result is probably an underestimate due to potential homoduplex mutants, especially at high frequency 22 . To test knock-in at sites other than TRAC, we generated another KIKO vector, TRAC KO ;GFP − PDCD1 KI (PDCD1-KIKO), to knock a green fluorescent protein (GFP) reporter into the Experiments were done with three infection replicates; quantifications and statistics are shown in Supplementary Fig. 4a . b, AAV-Cpf1-mediated GFP transgene knock-in into PDCD1 locus with TRAC knockout. Top, schematics of construct design for TRAC KO ;GFP-PDCD1 KI (PDCD1-KIKO). Bottom, flow cytometry plots showing representative PDCD1 GFP knock-in 5 d after AAV transduction (AAV6 packaging, MOI = 1 × 10 5 ). Experiments were done with six infection replicates; quantifications and statistics are shown in Supplementary Fig. 4b . c, AAV-Cpf1-mediated double knock-in with a single vector. Top, schematics of construct design for double-knock-in AAV vector dTomato-TRAC KI ;GFP-PDCD1 KI (TRAC-PDCD1-DKI), where dTomato and GFP are targeted to be integrated into the TRAC locus and the PDCD1 locus, respectively. Bottom, representative flow cytometry plots showing double knock-in 5 d after transduction of a single AAV construct (AAV6 packaging, MOI = 1 × 10 5 ). Experiments were done with 3-4 infection replicates; quantifications and statistics are shown in Supplementary Fig. 4c . d, AAV-Cpf1-mediated double knock-in with a two-vector system. Top, schematics of construct design for using both PDCD1 KO ;dTomato-TRAC KI and TRAC KO ;GFP-PDCD1 KI for dual targeting. Bottom, representative flow cytometry plots showing double knock-in 5 d after transduction of both AAV constructs (AAV6 packaging, MOI = 1 × 10 5 ). Experiments were done with three infection replicates; quantifications and statistics are shown in Supplementary Fig. 4d . e, Analysis of TCR-knockout efficiency in knock-in cells by FACS. Left, representative flow cytometry plots of the TCR expression levels in non-integration (Q4), single-integration (Q1, Q3), or double-integration (Q2) T cells from the two-vector system. An example workflow of FACS gating plots is shown in Supplementary Fig. 13 . Right, quantification of TCR − percentages in different quadrants shown in column graph (infection replicates, n = 3). Unpaired two-sided t-test was used to assess significance. TCR − population, vector versus dual targeting, **P < 0.01, ***P < 0.001. Data are shown as mean ± s.e.m.
PDCD1 locus while knocking out TRAC (Fig. 2b) . Similarly, AAV-Cpf1 PDCD1-KIKO achieved >80% TCR knockdown with stable GFP integration in near 30% of treated CD4 + T cells ( Fig. 2b and Supplementary Fig. 4b ).
The capacity to generate double knock-in in the same T cells is essential for multi-feature CAR-T cells such as bispecifics or multiple functional modulators. We then generated a dual-knock-in AAV vector, dTomato − TRAC KI ;GFP-PDCD1 KI (TRAC-PDCD1-DKI), Supplementary Fig. 6a . c, Quantitative allele mapping of TRAC locus for CD22BBz HDR, NHEJ, and WT reads with n = 3 infection replicates. Unpaired two-sided t-test was used to assess significance. WT group: vector versus unsorted, ***P < 0.001; vector versus sorted, ***P < 0.001; unsorted versus sorted, ***P < 0.001. NHEJ group: vector versus unsorted, ***P < 0.001; vector versus sorted, ***P < 0.001; unsorted versus sorted, not significant (NS). HDR group: vector versus unsorted, ***P < 0.001; vector versus sorted, ***P < 0.001; unsorted versus sorted, ***P < 0.001. Data are shown as mean ± s.e.m. d, Quantitative analysis for genomic knockout of PDCD1 by PDCD1 KO ;CD22BBz-TRAC KI in human primary CD4 + T cells. Unpaired two-sided t-test was used to assess significance. Vector versus unsorted, ***P < 0.001; vector versus sorted, ***P < 0.001; unsorted versus sorted, ***P < 0.001. Data are shown as mean ± s.e.m., plus individual data points on the graph. e, Time-course analysis of CAR transgene retention after transduction. CAR22 expression levels of PDCD1 KO ;CD22BBz-TRAC KI bulk targeted CAR-T cells are shown by dot plot (infection replicates, n = 3). The bulk T cells were stimulated once with mitomycin-C-treated NALM6 cells (CD22 + ; Supplementary Fig. 10a ) 5 d after transduction. We measured CAR expression by staining with a specific antibody and then carrying out flow cytometry. One-way ANOVA with Tukey's multiple-comparisons test was used to assess significance. **P < 0.01, ***P < 0.001. Data are shown as mean ± s.e.m., plus individual data points on the graph.
in which dTomato and GFP were targeted for integration into TRAC and PDCD1 loci, respectively. Five days after electroporation and AAV6-TRAC-PDCD1-DKI transduction, 7.54% double-positive GFP + dTomato + T cells were observed, along with 5.97% GFP and 6.82% dTomato single-positives ( Fig. 2c and Supplementary  Fig. 4c ). An alternative strategy with two different AAV vectors (PDCD1 KO ;dTomato-TRAC KI and TRAC KO ;GFP-PDCD1 KI ) for dual targeting produced on average 13.83% GFP + dTomato + , 17.23% GFP + , and 16.17% dTomato + T cells ( Fig. 2d and Supplementary  Fig. 4d ). All of the T cells that underwent integration (including single-and double-positives; Q1, Q2, and Q3) almost completely lost TCR expression, and 65% of non-integration T cells (GFP -dTomato -; Q4) lost TCR expression, whereas vector-transduced T cells mostly retained intact TCR ( Fig. 2e ). These data demonstrated simple, efficient, and precise double knock-in of transgenes in human T cells by AAV-Cpf1 with crRNA arrays and HDR donors.
One-step generation of TRAC knock-in CD22-specific CAR-T cells with PDCD1 disruption.
Integration of anti-CD19 CAR (CAR19) into TRAC can improve preclinical efficacy in leukemia, and specific knockouts can reduce T-cell exhaustion 11, 23, 24 . CD22-CAR targeting B-cell precursor ALL was safe and provided high response rates for pediatric patients who failed chemotherapy and/or CAR19 treatment 25, 26 . We generated a single AAV construct, PDCD1 KO ;CD22BBz-TRAC KI (CD22BBz KIKO, or CAR22 for short) for knocking CAR22 into TRAC with PDCD1 knockout (Fig. 3a) . Similarly, we showed that AAV-Cpf1 with CD22BBz KIKO generated precisely targeted knock-in and knockout with limited toxicity and high viability ( Fig. 3b and Supplementary  Fig. 5a,b ). With stimulation, the electroporated T cells quickly expanded over the course of the 26 d observed ( Supplementary  Fig. 5c ). Specifically, 44.6% of these T cells expressed CD22BBz CAR ( Fig. 3b and Supplementary Fig. 6a ). Semiquantitative In-Out PCR and NGS confirmed CD22BBz integration at the TRAC locus, where bulk HDR efficiency with single transduction reached 45.46% in unsorted cells and enriched to 81.88% in CD3 − CAR22 + -sorted cells ( Fig. 3c and Supplementary Fig. 6b ,c). NHEJ variants of TRAC also existed at 13.01% in bulk and 9.97% in sorted populations on average ( Fig. 3c ). Simultaneous PDCD1 knockout was observed at high efficiency at 59.73% in bulk and 90.39% in CD3 − CAR22 +sorted T cells on average ( Fig. 3d and Supplementary Fig. 6d ). Virtually no detectable on-target mutation was found in uninfected control, indicating a clean background. The fraction of CAR22 + T cells steadily increased over time, starting at 38.73% on day 3 and ramping up to 74.13% on day 9 after stimulation with target cells ( Fig. 3e and Supplementary Fig. 6e ), probably owing to negative selection of non-functional cells. These data demonstrate a simple and rapid method to generate targeted knock-in CAR with simultaneous immune-checkpoint knockout at high efficiency using the AAV-Cpf1 KIKO system in one step.
Modular generation of CD19 and CD22 bispecific CAR-T cells with double knock-in and dual-disruption.
We then tested whether AAV-Cpf1 KIKO can efficiently generate more complex CAR-T cells with simple engineering steps. We first generated an AAV vector, TRAC KO ;CD19BBz-PDCD1 KI (CD19BBz-KIKO), to mediate CD19BBz transgene knock-in into the PDCD1 locus with TRAC knockout ( Supplementary Fig. 7a ). We found that one transduction could generate CD19BBz-PDCD1 knock-in at a bulk efficiency of 37.83%, with efficient TRAC knockout (Supplementary Fig. 7b ,c). We then jointly transduced primary CD4 + T cells with both CD22BBz-KIKO and CD19BBz-KIKO vectors to generate bispecific CAR-T cells ( Supplementary Fig. 7d ). Five days after electroporation and transduction, FACS analysis revealed that one transduction generated dual knock-in of CD22BBz + CD19BBz + double-positive CAR-T cells at a bulk efficiency of 21.70%, with CD22BBz + and CD19BBz + single-positive cells at bulk efficiency of 22.53% and 7.27%, respectively ( Supplementary Fig. 7e ,f). All T cells that underwent integration (Q1, Q2, and Q3) had nearcomplete TCR disruption ( Supplementary Fig. 7g ). These results demonstrated one-step modular generation of engineered T cells with CD19BBz and CD22BBz double-knock-in and simultaneous TRAC;PDCD1 dual-disruption.
Comparing AAV-Cpf1 KIKO with Cas9-mediated single-and double-knock-in CAR-T cell generation. We then compared the AAV-Cpf1 KIKO platform with Cas9-mediated CAR-T cell generation by targeting the same CAR transgenes into the same loci. We first used Cas9 ribonucleoprotein (RNP) with annealed crRNA and tracrRNA for electroporation to introduce double-stranded breaks, then infected with AAVs carrying CAR HDR templates. This generated knock-in for CD22BBz CAR into the TRAC locus (CAR22), with an average of 44.40% CAR22 + T cells on day 5 ( Supplementary Fig. 8a,b ). This result was confirmed with two independent PDCD1 guide RNAs ( Supplementary Fig. 8b ). We also demonstrated CD19BBz CAR knock-in into the PDCD1 locus (CAR19) similarly ( Supplementary Fig. 8c,d ). We then performed double-knock-in using Cas9 RNP electroporation followed by AAV infection with both CD22BBz and CD19BBz HDR templates.
In parallel, we carried out the AAV-Cpf1 KIKO pipeline, namely, Cpf1 mRNA electroporation followed by infection of AAVs with crTRAC;crPDCD1 as well as CD22BBz and CD19BBz HDR templates. Notably, the AAV-Cpf1 KIKO double-knock-in pipeline efficiently generated CAR19 + CAR22 + double-positive cells averaging 35.80% on day 8 ( Fig. 4a and Supplementary Fig. 9a ), whereas the Cas9 RNP double-knock-in pipeline generated only 3.20% ( Fig. 4b and Supplementary Fig. 9b ). Using different guide RNAs did not change the efficiency of CAR19 + CAR22 + double-knock-in for the Cas9 RNP system ( Supplementary Fig. 9c ). The frequency of CAR19 + CAR22 + double-positive T cells generated by AAV-Cpf1 KIKO in the bulk unsorted population steadily increased from an average of 23.80% on day 5 to 61.73% on day 12 (Fig. 4c) , and up to 76.33% on days 14-16 (Supplementary Data 1). CAR19 + CAR22 + cells generated by the Cas9 RNP pipeline in the bulk unsorted population averaged 2.56% on day 5 to 4.06% on day 12 (Fig. 4d) . Although Cpf1 and Cas9 represent two different nucleases and the two systems do not have strict parity, these data show that, with the current approaches, the AAV-Cpf1 KIKO platform is highly efficient for generating endogenous genomic loci-targeted dual knock-in CAR-T cells. In vitro cytotoxic activity of CAR-T cells on cancer cells was measured by bioluminescence assay at different E/T ratios, using NALM6-GL cells stably transduced with GFP and luciferase genes as target cells ( Supplementary Fig. 10b,c) . The percentage of cancer cell death is shown for a titration series of E/T ratios for AAV-vector-transduced T cells. Two-way ANOVA with Tukey's multiple-comparisons test was used to assess significance (multiple-testing corrected). Cpf1 CD22BBz CAR versus vector, ***P < 0.001; Cas9 RNP CD22BBz CAR versus vector, ***P < 0.001; Cpf1 versus Cas9, NS. c, Representative flow cytometry results showing IFN-γ and TNF-α expression levels in Cpf1 CD22BBz KIKO versus Cas9 RNP CD22BBz CAR-T cells. IFN-γ and TNF-α production was tested by intracellular staining after coculture with NALM6 for 5 h at E/T = 1:1. Experiments were done with three infection replicates; quantifications and statistics are shown in Supplementary Fig. 12a . d, Representative flow cytometry results showing T-cell exhaustion marker expression level in Cpf1 CD22BBz KIKO versus Cas9 RNP CD22BBz CAR-T cells. PD-1, TIGIT, and LAG3 expression was tested by surface staining after coculture with NALM6 for 24 h at E/T = 0.5:1. Experiments were done with three infection replicates; quantifications and statistics are shown in Supplementary Fig. 12b . All data are shown as mean ± s.e.m., plus individual data points on the graph.
Immunological characteristics of single-and double-knockin CAR-T cells. We then compared the phenotypes of various CAR-T cells generated by the AAV-Cpf1 KIKO system. We used a cognate cancer cell line, NALM6 (CD19 + CD22 + ), and generated an NALM6-GL line that stably expressed GFP and luciferase ( Supplementary Fig. 10a-c) . We determined the cytolytic activity of CAR-T cells at different titration series of effector/target (E/T) ratios in a coculture setting (kill assay). Vector-transduced T cells had minimal cytolytic activity against NALM6-GL cells; in sharp contrast, all three forms of CAR-T cells generated by Cpf1 KIKO (CAR22, CAR19, and CAR22;CAR19 double-knock-in) had strong potency in killing NALM6-GL cancer cells in a dose-dependent manner ( Supplementary Fig. 11a ). These three forms of CAR-T cells had similar cytolytic activity ( Supplementary Fig. 11a ). We then measured the effector cytokine production and found that all three forms of CAR-T cells had highly boosted interferon (IFN)-γ and tumor necrosis factor (TNF)-α production compared with that of vector-transduced T cells ( Supplementary Fig. 11b,c) . The CAR22;CAR19 double-knock-in CAR-T cells had relatively higher TNF-α and lower IFN-γ productivity compared with that of their single-knock-in counterparts ( Supplementary Fig. 11b,c) . Thus, both single-and double-knock-in versions of AAV-Cpf1-KIKOgenerated CAR-T cells were robustly functional against cognate cancer cells.
Immunological characteristics of CAR-T cells generated by AAV-Cpf1 KIKO and Cas9-mediated knock-in and knockout.
We then examined the immunological characteristics of the CAR-T cells generated by the AAV-Cpf1 KIKO platform in parallel with Cas9-mediated knock-in and knockout (Fig. 5a ). We found that the CD22BBz CAR-T cells generated by both AAV-Cpf1 KIKO (Cpf1 KIKO CD22BBz) and Cas9-mediated knock-in and knockout (Cas9 RNP CD22BBz) were highly potent compared with vector-transduced T cells (Fig. 5b ). Both Cpf1-and Cas9-generated CAR-T cells were potent IFN-γ and TNF-α producers, at comparable levels ( Fig. 5c and Supplementary Fig. 12a ). Notably, in contrast to Cas9 RNP CD22BBz cells, the Cpf1 KIKO CD22BBz CAR-T cells expressed lower levels of T-cell exhaustion markers including PD-1, TIGIT, and LAG3 ( Fig. 5d and Supplementary  Fig. 12b ). These experiments demonstrated that the AAV-Cpf1 KIKO CAR-targeting method can generate engineered CAR-T cells with potent effector function and reduced levels of exhaustion with simpler transgene delivery, especially when involving the generation of double-knock-in CAR-T cells. Together with the production efficiency data above, these features suggest that AAV-Cpf1 KIKO is a favorable system for rapid and efficient generation of multi-feature CAR-T cells with genomic precision and modular characteristics.
Discussion

Genome engineering on immune cells such as T cells enables efficient introduction of multiple transgenes into different loci, which
can be widely used for studying gene functions in human primary T cells and characterizing mutant phenotypes. For example, the immunological characteristics of native or engineered T cells can be rapidly examined for important genes encoding immune checkpoints, master regulators, or previously unknown targets. The multiplexed knock-in and knockout capability can be harnessed to build various reporters or engineer logical circuitries into immune cells to analyze their endogenous expression or signaling pathways.
The KIKO system is in principle broadly applicable to various immune-cell types other than T cells, such as hematopoietic stem cells, dendritic cells, and macrophages. Adoptive transfer studies using these engineered cells can facilitate the study of pathological and therapeutic responses in animal models of diseases such as viral infection, immunological disorders, and cancer.
As a 'living drug' , genetically engineered CAR-T cells hold tremendous promise for potent and specific antitumor activity [6] [7] [8] . Currently, only two CAR-T platforms (Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel)) have received approval from the US Food and Drug Administration for treatment of large B-cell lymphomas such as non-Hodgkin lymphoma and B-cell ALL 4 . Most other leukemias and solid tumors do not have approved CAR-T therapy, although multiple preclinical and clinical studies are ongoing with various forms of CAR-T cells 5 . The generation of CAR-T cells involves primary T-cell isolation, transgene introduction, and expansion 27 . Transduction efficiency, transgene expression levels, and CAR stability or retention are all key to this process. However, in lentiviral or retroviral transduction, CAR-T cells tend to lose their transgenes and therefore the ability to recognize and destroy cancer cells 28 . CRISPR-Cas9-mediated TRAC knock-in improved CAR-T cell stability and function 11, 15 . The KIKO system uses AAV carrying both Cpf1 crRNA array for flexible multiplexed editing and HDR constructs for the introduction of CAR, thus offering important advantages. This system is readily scalable to high-dimensional CAR-T cell engineering such as dual targeting with two CARs and bispecifics 26, 29 , as well as the introduction of regulatory proteins such as autoregulatory motifs, kill switches, effector boosters, or dampeners 4 .
Given the high efficiency, rapid growth rate, and auto-enriching characteristics of the AAV-Cpf1 KIKO CAR-T cell, a regular blood draw can be used to generate a total number of 300 million CAR-T cells (a typical number for clinical infusion) with a number of electroporation-AAV reactions following in vitro expansion for approximately 2 weeks (Supplementary Data 1) 30 . Although this study provides proof of concept for a method that improves the early steps of CAR-T cell engineering, rigorous evaluation of toxicity profiles and in vivo efficacy testing need to be performed in the future before clinical applications. Given further optimization and in vivo testing, this platform, with its simplicity and modularity, has the potential to be broadly used as a research tool in T-cell engineering, as well as a pipeline for improved 'off-the-shelf ' adoptive T-cell therapies in the clinic.
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Methods
We developed a protocol for the generation of modular CAR-T cells as detailed in ref. 31 .
Institutional approval. This study has received institutional regulatory approval. All recombinant DNA and biosafety work was performed under the guidelines of Yale Environment, Health and Safety Committee with an approved protocol . All human sample work was performed under the guidelines of Yale University Institutional Review Board with an approved protocol (HIC 2000020784) .
T-cell culture. Human primary peripheral blood CD4 + T cells were acquired from healthy donors (STEMCELL Technologies, cat. no. 70026). Cells were obtained using Institutional Review Board-approved consent forms and protocols from the vendor (negative immunomagnetic separation techniques) (STEMCELL Technologies). T cells were cultured in X-VIVO media (Lonza) with 5% human AB (blood type) serum and recombinant human interleukin-2, 30 units (U) ml −1 . Before electroporation, T cells were activated with a 1:1 ratio of human anti-CD3/ anti-CD28 beads (CD3/CD28 Dynabeads, Thermo Fisher), which were later removed by magnetic separation rack after 2 d.
Generation of LbCpf1 mRNA. Human-codon-optimized LbCpf1 was from ref. 19 and was subcloned into a complementary DNA in vitro transcription vector. Pseudouridine-modified LbCpf1 mRNA with 5′ cap and poly(A) tail was generated from the vector at TriLink.
Construction of AAV vectors.
For the generation of an AAV crRNA expression vector (AAV-LbcrRNA, or pXD017), the U6-crRNA expression cassette with double BbsI cutting sites was synthesized and subcloned into an AAV backbone containing inverted terminal repeats. The LbCpf1 crRNA was designed by Benchling to target the first exon of the TRAC locus and the second exon of PDCD1 ( Supplementary Table 1 ). Oligonucleotides (Yale Keck) with sticky ends were annealed, phosphorylated, and ligated into BbsI-digested vector by T4 ligase (NEB). To generate the HDR construct, we amplified the left and right homologous arms of the TRAC or PDCD1 locus by PCR using locus-specific primer sets HDR-F1/R1 and HDR-F2/R2 from primary CD4 + T cells. For transgene cloning, the HDR-R1 and HDR-F2 were connected with a multiple cloning site ( Supplementary Table 1 ). Homologous donor templates were cloned into the AAV-LbcrRNA with or without a crRNA. CD22BBz CAR was generated as previously described 25 . Briefly, the CAR comprises a CD22-binding single chain variable fragment m971 specific for human CD22, followed by CD8 hingetransmembrane regions linked to 4-1BB (CD137) intracellular domains and CD3ζ intracellular domain. Based on a pXD017-dTomato backbone, m971-BBz was cloned into this vector using a gBlock (IDT). To generate CD19BBz CAR, we found the sequence of CD19-binding single-chain variable fragment (scFv) (FMC63) in NCBI (GenBank, HM852952) and used CD8 hinge-transmembrane regions linked to 4-1BB (CD137) intracellular domains and CD3ζ intracellular domain 32 . To detect CD19BBz CAR in a different way, we added the Flag-tag sequence (GATTACAAAGACGATGACGATAAG) after the CD8-α leader sequence 33 . Based on a pXD017-dTomato backbone, FMC63-BBz was cloned into this vector using a gBlock (IDT). For construction of the HDR template, the EFS-dTomato-PA cassette, EFS-CAR22BBz-PA, or EFS-CAR19BBz-PA cassette was cloned into the multi-clone site.
AAV production and titration. We produced AAV by transfecting HEK293FT cells (Thermo Fisher) in 15-cm tissue culture dishes (Corning). For transfection we used AAV2 transgene vectors, packaging (pDF6) plasmid, and AAV6/9 serotype plasmid together with polyethyleneimine. Transfected cells were collected with PBS 72 h after transfection. For the AAV purification, transfected cells were mixed with pure chloroform (1:10 volume) and incubated at 37 °C with vigorous shaking for 1 h. NaCl was added to a final concentration of 1 M, and then the samples were centrifuged at 20,000g at 4 °C for 15 min. The chloroform layer was discarded while the aqueous layer was transferred to another tube. PEG8000 was added to 10% (w/v) and shaken until dissolved. The mixture was incubated at 4 °C for 1 h and then centrifuged at 20,000g at 4 °C for 15 min. The supernatant was discarded and the pellet was suspended in Dulbecco's phosphate-buffered saline (DPBS) with MgCl 2 , treated with universal nuclease (Thermo Fisher), and incubated at 37 °C for 30 min. Chloroform (1:1 volume) was then added, shaken, and centrifuged at 12,000g at 4 °C for 15 min. The aqueous layer was isolated and concentrated through a 100-kDa molecular-weight cutoff filter (Millipore). Virus was titered by quantitative PCR using custom Taqman assays (Thermo Fisher) targeted to promoter U6.
T-cell electroporation. Electroporation was performed after T cells were activated for 2 d. After using a magnetic holder to remove CD3/CD28 Dynabeads, we prepared cells at a density of 2 × 10 5 cells per 10-μl tip reaction or 2 × 10 6 cells per 100-μL tip reaction in electroporation buffer R (Neon Transfection System Kits). T cells were mixed with 1 μg or 10 μg of modified NLS-LbCpf1 mRNA (TriLink) according to reaction volume and electric-shocked at program 24 (1,600 V, 10 ms, and 3 pulses). After electroporation, the cells were transferred into 1 ml of prewarmed X-VIVO media (without antibiotics) immediately. Indicated volumes of AAV at a defined MOI (specified in figure legends) were added to the T cells 2-4 h after electroporation.
Cas9 RNP electroporation. We produced ribonucleoproteins (RNPs) by complexing a two-component single guide RNA (sgRNA) to Cas9, as previously described 13 . In brief, Cas9 guide RNA was designed to target the same sites as Cpf1 crRNA for TRAC and PDCD1 using Benchling ( Supplementary Table 1 ). Cas9 crRNAs and tracrRNAs were chemically synthesized (Dharmacon or IDT) and resuspended in nuclease-free IDTE buffer at a concentration of 160 μM. The crRNA and tracrRNA were mixed at a 1:1 ratio and annealed as an sgRNA in nuclease-free IDTE buffer at 95 °C for 5 min and 37 °C for 10 min. Each guide was annealed separately and mixed as appropriate. RNPs were formed by the addition of SpCas9 nuclease (Dharmacon, IDT) with 80 μM gRNA (1:2 Cas9-to-sgRNA molar ratio) at benchtop for 15 min. RNPs were electroporated immediately after complexing. After 2-4 h, AAV6 was added into cells at MOI = 1 × 10 5 .
Generation of stable cell lines.
Lentiviruses including GFP-luciferase reporter genes were produced as described 34 . NALM6 cells (ATCC) were infected with 2× concentrated lentivirus by spinoculation in retronectin-coated (Takara) plates at 800g for 45 min at 32 °C. After infection for 2 d, the GFP + cells (NALM6-GL) were sorted on a BD FACSAria II. The second round of sorting was performed after culture for an additional 2 d. To test the luciferase expression in NALM6-GL, cells were incubated with 150 μg ml −1 D-luciferin (PerkinElmer) and bioluminescence signal intensity was measured by an IVIS system. Flow cytometry. Surface protein expression was determined by flow cytometry. After electroporation for 5 d, 1 × 10 6 cells were incubated with allophycocyanin (APC)-CD4, phycoerythrin (PE)/Cy7-TCR (or PE-TCR), and fluorescein isothiocyanate (FITC)-CD3 antibodies (Biolegend) for 30 min. For the CD22BBz CAR, transduced T cells were incubated with 0.2 μg of CD22-Fc (R&D Systems) in 100 μl of PBS for 30 min, and then stained with PE-IgG-Fc (Biolegend). For the CD19BBz CAR detection, the transduced T cells were stained with APC-anti-DYKDDDDK tag (Biolegend). Stained cells were measured and sorted on a BD FACSAria II. For the T-cell exhaustion assay, T cells from various groups were cocultured with NALM6 cells at a 0.5:1 E/T ratio for 24 h. Then, 1 × 10 6 cells were incubated with 0.2 μg of CD22-Fc (R&D Systems) in 100 μl of PBS for 30 min and then stained with PE-IgG-Fc, PD-1-FITC, TIGIT-APC, and LAG3-Percp/Cy5.5 (Biolegend) for 30 min. After being washed twice, the stained cells were measured and sorted on a BD FACSAria II, and analyzed with FlowJo software version 9.9.4 or 10.3 (Treestar).
Intracellular staining of IFN-γ and TNF-α.
Intracellular staining was performed to detect the expression level of IFN-γ and TNF-α. After infection for 4 d, AAVtransduced CD22BBz CAR-T cells were cocultured with NALM6 cells in fresh medium, which was supplied with brefeldin A and 2 ng ml −1 interleukin-2. After being incubated for 5 h, T cells were collected and stained for surface CAR. After membrane protein staining, cells were fixed and permeabilized by fixation/ permeabilization solution (BD), followed by the addition of anti-IFN-γ-APC or anti-TNF-α-FITC for intracellular staining. After 30 min, the stained cells were washed with BD Perm/Wash buffer and measured on a BD FACSAria II.
T cell/cancer cell coculture (kill assay). NALM6-GL cells (2 × 10 4 ) were seeded in a 96-well plate. The modified or control T cells were cocultured with NALM6-GL at indicated E/T ratios for 24 h. We tested cell proliferation by adding 150 μg ml −1 D-luciferin (PerkinElmer) into each well. After 5 min, luciferase assay intensity was measured by a plate reader (PerkinElmer).
Analysis of HDR by In-Out PCR.
A semiquantitative In-Out PCR was performed as previously described to measure the rates of dTomato or CAR22 m971-BBz integration at the TRAC locus 35 . The assay used three primers in one PCR reaction. One primer recognizes a sequence contained in the dTomato or m971-BBz cassette; a second primer binds to genomic sequence outside of this AAV donor; the third primer binds to a sequence of the left TRAC homology arm (Supplementary Table 1 ). This PCR product, designated TRAC-HDR, was normalized by comparison to the product resulting from the control with genomic DNA isolated from normal human CD4 + T cells.
Western blotting analysis. Cells were lysed in ice-cold RIPA buffer (Boston BioProducts) containing protease inhibitors (Roche, Sigma) and incubated on ice for 30 min. Protein supernatant was collected after centrifuging at 13,000g and 4 °C for 30 min. Protein concentration was determined via the Bradford protein assay (Bio-Rad). Protein samples were separated under reducing conditions on 4-15% Tris-HCl gels (Bio-Rad) and analyzed by western blotting using primary mouse anti-LbCpf1 (Diagenode; 1:3,000) followed by secondary anti-rabbit HRP antibodies (Sigma-Aldrich; 1:10,000). Blots were imaged with an Amersham Imager 600.
Amplicon sequencing. The resultant PCR products were used for Nextera library preparation according to the manufacturer's protocols (Illumina). Briefly, 1 ng purified PCR product was fragmented and tagged using the Nextera Amplicon Tagment Mix according the to manufacturer's recommendations, after which limited-cycle PCR was carried out with indexing primers and Illumina adaptors. After this amplification, DNA bands were purified with a gel extraction kit (Qiagen). Libraries were sequenced using 100-base-pair (bp) paired-end reads on an Illumina HiSeq 4000 instrument or equivalent, in general generating between 29 million and 74 million reads per library. For indel quantification, paired reads were mapped to the amplicon sequences using BWA-MEM with the -M option. Then, 100-bp reads from the SAM file that fully mapped within a ±75-bp window of the expected cut site within the amplicon were identified (soft-clipped reads were discarded). Indel reads were then identified by the presence of 'I' or 'D' characters in the CIGAR string. Cutting efficiency was quantified as a percentage of indels over total (indel plus WT) reads within the defined window. Indel variant statistics are provided in Supplementary Data 1, and the raw sequencing files are available via SRA (see 'Data availability' section).
HDR mapping. For HDR quantification, FASTQ reads were mapped to possible amplicons on the basis of primer combinations and HDR status. Mapping was performed for full amplicons and for 'informative' amplicons, which were truncated so that 100-bp reads would have at least 20-bp homology with the CAR sequence (or with the other TRAC arm, in the case of WT sequences). Informative reads would be used to distinguish WT, NHEJ, and HDR reads with higher confidence. Paired reads were mapped to amplicon sequences using BWA-MEM with the -M flag to generate SAM files. SAMtools was used to convert files to BAM and to sort, index, and generate summary statistics of read counts with the idxstats option. To quantify WT versus NHEJ reads, we took reads that mapped to the "info_nonHDR" sequence (described below) and called reads with indels (I or D characters within the CIGAR string) as NHEJ. Otherwise, we called reads as WT. Read counts were then pooled for downstream analysis. A description of amplicon sequences follows:
• amplicon_nonHDR: full amplicon from F1 and R1 of genomic, WT DNA • amplicon_CAR_F1: full amplicon from F1 and R1 of expected, integrated CAR • amplicon_CAR_F2: full amplicon from F2 (primer site within the CAR as opposed to outside) and R1 of expected, integrated CAR • info_nonHDR: same as amplicon_nonHDR, except truncated to 80 bp of the TRAC arms • info_CAR_F1: same as amplicon_CAR_F1, except truncated to 80 bp of the TRAC arms flanking the TRAC-CAR interface • info_CAR_F2: same as amplicon_CAR_F2, except truncated to 80 bp of the TRAC arms flanking the TRAC-CAR interface (relevant to the right arm only, as F2 is within the CAR sequence) HDR, NHEJ, and WT scores were calculated as follows:
HDR statistics are provided in Supplementary Data 1, and the raw sequencing files are available via SRA (see 'Data availability' section).
Standard statistical analysis (non-NGS).
Standard data analyses (non-NGS) were performed using regular statistics, whereas NGS data were analyzed with specific pipelines described above. Data comparison between two groups was done by twotailed unpaired t-test or non-parametric Wilcox test, and P values and statistical significance were estimated for all analyses. Data comparison between multiple groups with two factors was done by two-way analysis of variance (ANOVA), and P values and statistical significance were estimated for all pair-wise comparisons and adjusted for multiple testing. Prism (GraphPad) and RStudio were used for these analyses. All statistics are provided in Supplementary Data 1. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
nature research | reporting summary
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
No specific software was used for data collection.
Data analysis
Flow cytometric data was analyzed using FlowJo v9.9.4 and v.10.3. Amplicon sequencing was analyzed using BWA-MEM with the -M option.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. 
Mycoplasma contamination
All cell lines used in this study tested negative for mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)
No commonly misidentified lines were used in the study.
Human research participants
Policy information about studies involving human research participants
Population characteristics
Human primary CD4+ T cells were taken from healthy human donors. Certificates are available from STEMCELL TECHNOLOGIES. Population characteristics were not available from because the primary T cell sources were de-identified.
Recruitment
Human primary CD4+ T cells were taken from healthy human donors by STEMCELL TECHNOLOGIES. There is a potential selection bias due to the small number of donors' T cells used, which might slightly affect the viral transduction efficiency. The potential genetic variations in human population, if happen at the targeted loci, might affect gene targeting.
Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
Surface staining for flow cytometry and cell sorting was performed by pelleting cells and resuspending in 50 μL of FACS Buffer (2% FBS in PBS) with antibodies (1:100 dilution) for 30 minutes at 4C in the dark. Cells were washed once in FACS buffer before resuspension. For the intracellular staining, cells were fixe and permeabilized by fixation/permeabilization solution (BD) for 20 min. and resuspending in 50 μL of permeabilization/wash Bufferwith antibodies (1:100 dilution) for 30 minutes at 4C in the dark. Cells were washed once in FACS buffer before resuspension.
Instrument
Flow cytometric analysis was performed on an BD FACSAria II
Software
FlowJo v.10.3 was used for flow ctyometry data analysis.
Cell population abundance 0.1 million of TCR negative cells were sorted. The sorted cells were re-measured by FACS to confirm the purity.
Gating strategy
A lymphocyte gate was defined first from FSC-A v SSC-A. Singlet gates were then defined on FSC-H v FSC-W. Additional gating was performed as described in figure and extended data legends for individual experiments.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
